Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by Se
Go back to Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by Se| (NASDAQ: SRRK) | Delayed: 46.65 -2.37 (4.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.02 | 52 Week High | $ | |||
| Open | $48.02 | 52 Week Low | $ | |||
| Day High | $48.53 | P/E | N/A | |||
| Day Low | $45.88 | EPS | $ | |||
| Volume | 3,253,091 | |||||
